Shares of Boston Scientific Corporation (NYSE:BSX) ended Wednesday session in red amid volatile trading. The shares closed down -0.41 points or -1.84% at $21.84 with 17.14 million shares getting traded. Post opening the session at $21.98, the shares hit an intraday low of $21.20 and an intraday high of $22.24 and the price vacillated in this range throughout the day. The company has a market cap of $30.02 billion and the numbers of outstanding shares have been calculated to be 1.36 billion shares.
Boston Scientific Corporation (BSX) recently declared the acquisition of the LumenR™ Tissue Retractor System from LumenR LLC, a privately held Newark, California based company. The LumenR Tissue Retractor System is presently in development for use during endoscopic resection of lesions in the colon, esophagus or stomach.
The LumenR system is designed to improve endoscopic sub-mucosal dissection (ESD) and endoscopic mucosal resection (EMR) procedures which are less invasive alternatives to conventional surgery for the removal of precancerous lesions and malignant tumors in the gastrointestinal tract. The system will facilitate improved visualization of lesions and create a stable working environment to support tissue retraction and resection during these procedures.
Shares of Medtronic PLC (NYSE:MDT) ended Wednesday session in red amid volatile trading. The shares closed down -1.48 points or -1.75% at $82.86 with 9.80 million shares getting traded. Post opening the session at $82.67, the shares hit an intraday low of $81.65 and an intraday high of $84.07 and the price vacillated in this range throughout the day. The company has a market cap of $114.51 billion and the numbers of outstanding shares have been calculated to be 1.38 billion shares.
Medtronic PLC (MDT) declared the Health Canada licence and the first Canadian implants of the new Specify™ SureScan™ MRI surgical leads, which are indicated for use as part of Medtronic’s implanted neurostimulation systems (also known as spinal cord stimulation, or SCS) for chronic pain. In 2013, Medtronic introduced the first implantable neurostimulation systems for use in the treatment of chronic, intractable back and/or limb pain that are licenced for full-body Magnetic Resonance Imaging (MRI) scans under specified conditions. The licencing of Specify SureScan MRI surgical leads establishes Medtronic as the only company in Canada with a full portfolio of SCS systems licenced by Health Canada for full-body MRI. This means physicians in Canada can now offer a Medtronic full-body MR Conditional SCS system best suited for their patients regardless of the type of neurostimulator (rechargeable or non-rechargeable) or lead type (percutaneous or surgical).